126 related articles for article (PubMed ID: 16353247)
1. Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer.
Nagakawa O; Yamagishi T; Akashi T; Nagaike K; Fuse H
Prostate; 2006 Apr; 66(5):447-52. PubMed ID: 16353247
[TBL] [Abstract][Full Text] [Related]
2. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
3. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
4. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
5. Serum keratinocyte growth factor measurement in patients with prostate cancer.
Mehta PB; Robson CN; Neal DE; Leung HY
J Urol; 2000 Dec; 164(6):2151-5. PubMed ID: 11061946
[TBL] [Abstract][Full Text] [Related]
6. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
Kirchhofer D; Peek M; Lipari MT; Billeci K; Fan B; Moran P
FEBS Lett; 2005 Mar; 579(9):1945-50. PubMed ID: 15792801
[TBL] [Abstract][Full Text] [Related]
7. Changes in plasma levels of hepatocyte growth factor and its associated factors during pregnancy.
Watanabe T; Sakata Y; Matsubara S; Yamagishi T; Nagaike K; Kuwata T; Suzuki M
J Obstet Gynaecol Res; 2006 Feb; 32(1):10-4. PubMed ID: 16445520
[TBL] [Abstract][Full Text] [Related]
8. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
[TBL] [Abstract][Full Text] [Related]
9. The role of hepatocyte growth factor activator inhibitor-1 (HAI-1) as a prognostic indicator in cervical cancer.
Nakamura K; Abarzua F; Hongo A; Kodama J; Nasu Y; Kumon H; Hiramatsu Y
Int J Oncol; 2009 Aug; 35(2):239-48. PubMed ID: 19578736
[TBL] [Abstract][Full Text] [Related]
10. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
[TBL] [Abstract][Full Text] [Related]
11. Expression of Hepatocyte growth factor activator inhibitor type-1 (HAI-1) in prostate cancer.
Yasuda K; Komiya A; Watanabe A; Morii A; Oya T; Nagakawa O; Fujiuchi Y; Fuse H
Anticancer Res; 2013 Feb; 33(2):575-81. PubMed ID: 23393351
[TBL] [Abstract][Full Text] [Related]
12. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
Bergum C; List K
Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
[TBL] [Abstract][Full Text] [Related]
13. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma.
Nagata K; Hirono S; Ido A; Kataoka H; Moriuchi A; Shimomura T; Hori T; Hayashi K; Koono M; Kitamura N; Tsubouchi H
Biochem Biophys Res Commun; 2001 Nov; 289(1):205-11. PubMed ID: 11708800
[TBL] [Abstract][Full Text] [Related]
14. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
15. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance.
Hu C; Jiang N; Wang G; Zheng J; Yang W; Yang J
J BUON; 2014; 19(1):215-20. PubMed ID: 24659667
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.
Itoh H; Kataoka H; Hamasuna R; Kitamura N; Koono M
Biochem Biophys Res Commun; 1999 Feb; 255(3):740-8. PubMed ID: 10049781
[TBL] [Abstract][Full Text] [Related]
17. [Plasma chromogranin-A (CgA)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract][Full Text] [Related]
18. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
19. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
20. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection.
D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH
Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
